Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency Pharmaceutical Investing
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMY, LSPD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, CTXS, STNE INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HEPS, PTON and Z Pharmaceutical Investing
BMY, LSPD SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
Trodelvy® Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line Pharmaceutical Investing
